×
About 1,618 results

ALLMedicine™ Sensory Neuropathy Center

Research & Reviews  612 results

Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395481
Current Oncology (Toronto, Ont.); Sempere-Bigorra M, Julián-Rochina I et. al.

Aug 27th, 2021 - Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects o...

Acetylcholine receptor antibodies in a patient with sensory neuropathy.
https://doi.org/10.1016/j.jneuroim.2021.577692
Journal of Neuroimmunology; Sriwastava S, Lisak RP

Aug 18th, 2021 - Antibodies to acetylcholine receptor (AChR) are detected in the vast majority of patients with generalized myasthenia gravis (MG) and are rarely detected in significant titer in other autoimmune diseases. We report a patient with an axonal predomi...

Large-scale prospective genome-wide association study of oxaliplatin in stage II/III co...
https://doi.org/10.1016/j.annonc.2021.08.1745
Annals of Oncology : Official Journal of the European Soc... Kanai M, Kawaguchi T et. al.

Aug 16th, 2021 - The severity of oxaliplatin (L-OHP)-induced peripheral sensory neuropathy (PSN) exhibits substantial interpatient variability, and some patients suffer from long-term, persisting PSN. To identify single-nucleotide polymorphisms (SNPs) predicting L...

Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS): genetic and c...
https://doi.org/10.1136/practneurol-2020-002822
Practical Neurology; Cortese A, Curro' R et. al.

Aug 15th, 2021 - Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) typically presents in middle life with a combination of neuropathy, ataxia and vestibular disease, with patients reporting progressive imbalance, oscillopsia, sensory disturb...

see more →

Guidelines  1 results

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on man...
https://doi.org/10.1111/j.1529-8027.2010.00278.x
Journal of the Peripheral Nervous System : JPNS;

Nov 3rd, 2010 - The aim of this guideline is to update the 2006 EFNS/PNS guideline on management of patients with a demyelinating neuropathy and a paraprotein (paraproteinemic demyelinating neuropathy [PDN]) by review of evidence and expert consensus. In the abse...

see more →

News  33 results

Acute Encephalopathy Following Hyperbaric Oxygen Therapy in a Patient on Metronidazole
https://www.mdedge.com/fedprac/avaho/article/198441/neurology/acute-encephalopathy-following-hyperbaric-oxygen-therapy/page/0/2?channel=263

Apr 8th, 2019 - Conclusion This patient’s highly specific MRI findings, neurologic examination consistent with confusion, ataxia, length-dependent sensory neuropathy, and 360-g cumulative dose of metronidazole over the previous 6 months suggest he experienced MIE.

FDA approves daratumumab split-dosing regimen in MM
https://www.mdedge.com/hematology-oncology/article/194430/multiple-myeloma/fda-approves-daratumumab-split-dosing-regimen-mm?channel=39313
Lucas Franki

Feb 13th, 2019 - The Food and Drug Administration has approved a split-dosing regimen for daratumumab (Darzalex) in patients with multiple myeloma, allowing the first infusion to be split over 2 days. FDA approval is based on results from the global, multi-arm, ph.

Daratumumab approved in Europe for new myeloma indication
https://www.mdedge.com/hematology-oncology/article/173937/multiple-myeloma/daratumumab-approved-europe-new-myeloma/page/0/1

Sep 4th, 2018 - The median progression-free survival (PFS) was not reached in the D-VMP arm and was 18. 1 months in the VMP arm.

Daratumumab approved for new indication in MM
https://www.mdedge.com/hematology-oncology/article/184740/multiple-myeloma/daratumumab-approved-new-indication-mm
HT Staff

Sep 1st, 2018 - Photo courtesy of Janssen Daratumumab (Darzalex) The European Commission (EC) has approved a new indication for daratumumab (Darzalex®). The drug is now authorized for use in combination with bortezomib, melphalan, and prednisone (VMP) to treat ad.

Status Report: Expert Reviews Guideline-Based Options in Advanced CRC
https://www.onclive.com/publications/oncology-live/2018/vol-19-no-12/status-report-expert-reviews-guidelinebased-options-in-advanced-crc

Jun 13th, 2018 - Rona D. Yaeger, MD Three months of adjuvant chemotherapy could be a viable option for most patients with advanced colorectal cancer (CRC), and the addition of targeted therapy should be considered for those with metastatic disease. All patients di...

see more →

Patient Education  1 results see all →